Harrow(us:HROW)
26.60
+1.49%
Updated on 2025-03-31
Open:25.52
Close:26.60
High:26.75
Low:24.78
Prev Close:26.21
Volume:796021.00
Turnover:20.75M
Turnover Ratio:2.23%
Shares:35.65M
MarketCap:948.40M
About Harrow
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Company Name: Harrow
Address: 102 Woodmont Boulevard,Suite 610
Employees: 315
Fiscar Year: 12-31
IPO Date: 2013-02-08
Website: http://www.harrowinc.com
CIK: 1360214
View all SEC Filings
About
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Address:102 Woodmont Boulevard,Suite 610
Website:http://www.harrowinc.com
Market Movers